We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

142 hedge funds and large institutions have $739M invested in CytomX Therapeutics in 2018 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 44 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

128% more call options, than puts

Call options by funds: $2.74M | Put options by funds: $1.2M

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

41% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 44

6.11% more ownership

Funds ownership: 77.05% → 83.16% (+6.1%)

8% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 24

1% more funds holding

Funds holding: 141 → 142 (+1)

12% less capital invested

Capital invested by funds: $843M → $739M (-$104M)

Holders
142
Holders Change
+1
Holders Change %
+0.71%
% of All Funds
3.25%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
26
Increased
62
Reduced
44
Closed
24
Calls
$2.74M
Puts
$1.2M
Net Calls
+$1.54M
Net Calls Change
-$1.01M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$18.3M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$16.7M
3
State Street
State Street
Massachusetts
+$14.3M
4
Renaissance Technologies
Renaissance Technologies
New York
+$11.5M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.63M

Top Sellers

Rank Fund Capital Flow
1
TG
TRV GP
Massachusetts
-$29M
2
Millennium Management
Millennium Management
New York
-$8.43M
3
TCM
Tekla Capital Management
Massachusetts
-$7.54M
4
PA
Perceptive Advisors
New York
-$7.33M
5
PC
PointState Capital
New York
-$4.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$5.51M +$795K +31,127 +15%
Charles Schwab
27
Charles Schwab
California
$5.39M +$959K +37,560 +19%
PAM
28
Panagora Asset Management
Massachusetts
$4.93M +$1.45M +56,734 +36%
CC
29
Casdin Capital
New York
$4.74M – – –
CS
30
Candriam SCA
Luxembourg
$4.12M +$3.55M +139,127 +339%
PAG
31
Private Advisor Group
New Jersey
$3.84M +$4.22M +165,231 New
TA
32
Teachers Advisors
New York
$3.77M +$533K +20,885 +15%
GIM
33
Granahan Investment Management
Massachusetts
$3.71M -$2.25K -88 -0.1%
Point72 Asset Management
34
Point72 Asset Management
Connecticut
$3.62M +$4.04M +158,171 New
American Century Companies
35
American Century Companies
Missouri
$3.55M -$1.27M -49,743 -24%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$3.55M +$504K +19,749 +15%
JP Morgan Chase
37
JP Morgan Chase
New York
$3.2M -$1.56M -61,130 -30%
First Trust Advisors
38
First Trust Advisors
Illinois
$3.12M +$3.49M +136,638 New
Bank of America
39
Bank of America
North Carolina
$2.94M -$1.82M -71,077 -36%
Russell Investments Group
40
Russell Investments Group
United Kingdom
$2.9M -$1.64M -64,382 -34%
Victory Capital Management
41
Victory Capital Management
Texas
$2.68M -$171K -6,710 -5%
BIM
42
Bogle Investment Management
Massachusetts
$2.59M +$221K +8,639 +8%
Morgan Stanley
43
Morgan Stanley
New York
$2.53M -$602K -23,563 -18%
CPC
44
Congress Park Capital
New York
$2.5M +$46K +1,800 +2%
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$2.47M +$780K +30,538 +39%
VIA
46
Vident Investment Advisory
Georgia
$2.28M +$530K +20,761 +26%
AllianceBernstein
47
AllianceBernstein
Tennessee
$2.24M +$608K +23,800 +32%
Deutsche Bank
48
Deutsche Bank
Germany
$2.17M +$279K +10,939 +13%
Wells Fargo
49
Wells Fargo
California
$2.08M +$801K +31,364 +53%
SFM
50
Sphera Funds Management
Israel
$1.9M -$2.47M -96,858 -54%
1
2
3 4 5

CTMX Hedge Fund Activity: Q2 2018 in Review

142 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2018, worth a combined $739M — down 12% from $843M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CTMX positions and 24 closed out — a net gain of 2 holders — while 62 added to existing stakes and 44 trimmed.

The largest buyer was BlackRock, adding an estimated $18.3M. The largest seller was TRV GP, exiting entirely with an estimated $29M sold.

  • 142 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2018, up from 141 in Q1 2018.
  • Funds reported $739M of CytomX Therapeutics stock for Q2 2018, down 12% quarter-over-quarter.
  • 26 funds opened new CytomX Therapeutics positions in Q2 2018 and 24 closed out, a net change of +2 holders.
  • The largest CytomX Therapeutics buyer in Q2 2018 was BlackRock, an estimated $18.3M added.
  • The largest CytomX Therapeutics seller in Q2 2018 was TRV GP, an estimated $29M sold.

Based on aggregated 13F filings for Q2 2018.